Adagene Inc. (ADAG)
| Market Cap | 244.47M +268.0% |
| Revenue (ttm) | 7.67M +7,332.8% |
| Net Income | -17.61M |
| EPS | -0.38 |
| Shares Out | 66.07M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,317 |
| Open | 3.640 |
| Previous Close | 3.660 |
| Day's Range | 3.590 - 3.725 |
| 52-Week Range | 1.300 - 4.750 |
| Beta | 0.57 |
| Analysts | Strong Buy |
| Price Target | 8.25 (+122.97%) |
| Earnings Date | Apr 1, 2026 |
About ADAG
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 ... [Read more]
Financial Performance
In 2025, Adagene's revenue was $7.67 million, an increase of 7332.76% compared to the previous year's $103,204. Losses were -$17.61 million, -47.32% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ADAG stock is "Strong Buy." The 12-month stock price target is $8.25, which is an increase of 122.97% from the latest price.
News
Adagene to Participate in Two Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based thera...
Adagene presents data from two Phase 1b/2 studies of muzastotug at AACR
Adagene (ADAG) presented new data from two ongoing Phase 1b/2 studies of muzastotug in triple combination regimens at the American Association of Cancer Research annual meeting 2026, held April 17-22…
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively...
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
SAN DIEGO and SUZHOU, China, April 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and developm...
Adagene price target raised to $10 from $9 at Guggenheim
Guggenheim raised the firm’s price target on Adagene (ADAG) to $10 from $9 and keeps a Buy rating on the shares. The firm is updating its model for FY25 earnings,…
Adagene 18.666M share Spot Secondary priced at $3.75
Leerink and LifeSci Capital acted as joint book running managers for the offering.
Adagene enters pact with Incyte for combination of muzastotug, INCA33890
Adagene (ADAG) announced a clinical collaboration with Incyte (INCY) to evaluate the combination of muzastotug and INCA33890, a TGFbetaR2 PD-1 bispecific antibody, in patients with microsatellite stab...
Adagene announces results from the latest data cut of muzastotug study
Adagene (ADAG) announced results from the latest data cut from its Phase 1b/2 study of muzastotug in patients with advanced microsatellite stable colorectal cancer with no liver metastases. FDA has…
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a company committed to transforming the discovery and development of novel ant...
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
Dose-Dependent Efficacy Results : As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement o...
Adagene reports FY25 EPS (24c) vs (51c) last year
Reports FY25 revenue $7.7M vs $103,000 last year. “Our clinical data for muzastotug plus pembrolizumab consistently demonstrate potent, dose-dependent efficacy,” said Peter Luo, Ph.D., Chairman and Pr...
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, ...
Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based the...
Adagene Transcript: Leerink Global Healthcare Conference 2026
ADG126 demonstrates strong efficacy and safety in late-line MSS CRC, with higher doses yielding better response rates and durability. Strategic collaborations and pipeline expansion target additional indications and novel combinations, with upcoming data expected to further validate the program.
Adagene Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
ADG126, a masked anti-CTLA-4 antibody, is showing promising efficacy and safety in late-line MSS-CRC without liver metastases, with response rates up to 29% and median survival of 19–20 months. Strategic collaborations, notably with Sanofi, support ongoing trials and future expansion.
Adagene provides objective for 2026
2026 Objectives: Q1 2026: Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC, including 41 patients in the 10 mg/kg cohorts and 26…
Adagene Provides Business Update and 2026 Objectives
Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026 Unaudited cash and cash equivalents of $74.5 million as of December 31,...
Adagene announces FDA fast track designation for muzastotug
Adagene (ADAG) announced that the U.S. Food and Drug Administration, FDA, has designated muzastotug, in combination with Merck’s (MRK) anti-PD-1 therapy, KEYTRUDA, as a Fast Track product for adult pa...
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc...
Adagene initiated with a Buy at Guggenheim on muzastotug potential
As previously reported, Guggenheim initiated coverage of Adagene (ADAG) with a Buy rating and $9 price target The company’s lead product candidate muzastotug is currently in Phase 2 for patients…
Adagene initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Adagene (ADAG) with a Buy rating and $9 price target
Adagene initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Adagene (ADAG) with an Outperform rating and $8 price target
Adagene announces licensing agreement with Third Arc Bio
Adagene (ADAG) announced a licensing agreement under which Third Arc Bio will utilize Adagene’s SAFEbody technology platform to generate masked CD3 T cell engagers against unique tumor associated anti...
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
SAN DIEGO and SUZHOU, China and SPRING HOUSE, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) and Third Arc Bio, Inc. (“Third Arc Bio”), today announced a licensing agre...